Latest Conference Articles

Olaparib and radium-223 bested radium-223 alone in radiographic progression-free survival in men with castration-resistant prostate cancer.

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical cancer.

Meghan Mooradian, MD, discusses findings and implications of the phase 2 NEO-MEL-T study.

Darolutamide significantly delayed pain progression and improved overall well-being in patients with metastatic hormone-sensitive prostate cancer.

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in high-risk locally advanced cervical cancer, establishing a new standard of care.

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety.

DeLLphi-304 trial results showed tarlatamab significantly improved PFS and OS over chemotherapy in second-line SCLC, establishing it as a new standard.

A prophylactic dermatologic regimen significantly reduced skin side effects and improved quality of life for NSCLC patients on amivantamab/lazertinib.

J. Randolph (Randy) Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

Benmelstobart alone or with anlotinib improved progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Atezolizumab plus cabozantinib or cabozantinib alone showed efficacy and manageable safety in second-line renal cell carcinoma.

The ALNEO trial's final analysis shows neoadjuvant alectinib is effective and well tolerated in resectable stage III ALK-positive NSCLC, achieving 42% MPR and 67% ORR, suggesting a feasible perioperative option.

Niraparib with AAP cut the risk of progression or death by 37% in HRR-altered mCSPC, according to data from the AMPLITUDE trial.

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.

The first-line regimen of disitamab vedotin, toripalimab, and trastuzumab revealed superior efficacy and response rates vs disitamab vedotin, toripalimab, and chemotherapy in HER2-expressing locally advanced or metastatic G/GEJ cancer.

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of exploring therapies with CNS penetration in this space.

In the VERIFY study, rusfertide significantly improved clinical responses vs placebo in polycythemia vera, offering a potential new therapy in the space.

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall survival.

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting further development.

Patritumab deruxtecan did not improve overall survival compared to chemotherapy in EGFR-mutated NSCLC, despite showing PFS and ORR benefits previously.

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.

Extended follow-up of MonumenTAL-1 shows talquetamab-tgvs yields durable ORRs and promising survival outcomes in relapsed/refractory multiple myeloma, with a tolerable safety profile.

Shlomo Koyfman, MD, discusses the MK-3475-630/​KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer.

Ribociclib combined with aromatase inhibitors shows significant survival benefits for early-stage hormone receptor-positive breast cancer, enhancing treatment outcomes across patient demographics.

T-DXd plus pertuzumab significantly extended PFS (40.7 vs 26.9 months) in HER2+ metastatic breast cancer, suggesting a new frontline standard of care.

The SACHI trial showed savolitinib + osimertinib significantly improved PFS (8.2 vs 4.5 months) vs chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR TKI progression.

EMBER-3 trial results show imlunestrant, alone or with abemaciclib, improves patient-reported outcomes for ER+/HER2- advanced breast cancer after endocrine therapy.

The NeoSTAR trial showed neoadjuvant sacituzumab govitecan and pembrolizumab achieved a 32% pCR rate in early-stage TNBC, with promising efficacy and a tolerable safety profile.